Navigation Links
Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
Date:10/25/2010

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences -- CARMIEL, Israel, Oct. 25 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences

 

CARMIEL, Israel, Oct. 25 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the Oppenheimer 21st Annual Healthcare Conference in New York and the World Orphan Drug Congress 2010 in Geneva. The conference schedule is as follows:Oppenheimer 21st Annual Healthcare ConferenceCorporate Presentation, November 2 at 12:00 PM ETWaldorf Astoria Hotel, New York, NYA webcast of this presentation will be available at www.protalix.com on the event calendar pageWorld Orphan Drug Congress 2010Presentation, November 30 at 9:10 AM CESTCrown Plaza Hotel, Geneva, SwitzerlandAbout ProtalixProtalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system.  Protalix's ProCellEx™ presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses.  Protalix is also advancing additional recombinant biopharmaceutical drug development programs.  Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease. The Company's new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.

Investor Contact: Marcy NanusThe Trout Group, LLCTelephone: 646-378-2927Email: mnanus@troutgroup.com
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
2. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
3. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
4. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
5. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
6. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
7. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
8. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
9. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/26/2016)... , April 26, 2016 Diplomat Pharmacy, ... of Jennifer Hagerman , Pharm D., to Vice ... growing role at Diplomat, Hagerman will continue to lead ... company that delivers custom education and training to Diplomat ... specialty pharmacy industry. Diplomat University also houses the quality ...
(Date:4/26/2016)... , April 26, 2016 Research ... and Credit Risk Analysis of the Biological Medicine Industry ... This comprehensive report analyzes the financial assessment and credit ... China . The report provides readers with an ... all market participants should be aware of. It considers ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 2016 , ... One way to ignore solid evidence is to dismiss research ... toss the baby out with the bathwater when we ignore all studies because some ... and otherwise making better use of education policy research. , “When readers heed basic ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... USA Medical Card reminds us that May ... (CDC), a stroke is the fourth leading cause of death in the United States; someone ... almost a quarter of them in individuals under 65 years old. A stroke is ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... today announced a new Residency Education & Collaboration Platform for hospitals and ... resources, and a host of collaboration tools designed to improve patient outcomes ...
(Date:4/28/2016)... ... 2016 , ... A first-time look at workers’ compensation claims in Kentucky found ... Compensation Research Institute (WCRI) announced, and that costs per claim were stable between ... Edition , found that indemnity costs per claim and benefit delivery expenses per claim ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... has partnered with Community Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty ... of oncology by introducing an accreditation distinction. ACHC provides a wide range of ...
Breaking Medicine News(10 mins):